Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Identification of a postendocytic sorting sequence in CCR5.

Delhaye M, Gravot A, Ayinde D, Niedergang F, Alizon M, Brelot A.

Mol Pharmacol. 2007 Dec;72(6):1497-507. Epub 2007 Sep 12.

PMID:
17855654
2.

Detection of cell-cell fusion mediated by Ebola virus glycoproteins.

Bär S, Takada A, Kawaoka Y, Alizon M.

J Virol. 2006 Mar;80(6):2815-22.

3.

On the dimerization of CCR5.

Lemay J, Marullo S, Jockers R, Alizon M, Brelot A.

Nat Immunol. 2005 Jun;6(6):535; author reply 535-6. No abstract available.

PMID:
15908929
5.

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.

Hartley O, Gaertner H, Wilken J, Thompson D, Fish R, Ramos A, Pastore C, Dufour B, Cerini F, Melotti A, Heveker N, Picard L, Alizon M, Mosier D, Kent S, Offord R.

Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16460-5. Epub 2004 Nov 15.

7.

Rescue of HIV-1 receptor function through cooperation between different forms of the CCR5 chemokine receptor.

Chelli M, Alizon M.

J Biol Chem. 2002 Oct 18;277(42):39388-96. Epub 2002 Aug 1.

8.

HIV-1 entry and how to block it.

Brelot A, Alizon M.

AIDS. 2001;15 Suppl 5:S3-11. Review. No abstract available.

PMID:
11816172
9.

Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor.

Chelli M, Alizon M.

J Biol Chem. 2001 Dec 14;276(50):46975-82. Epub 2001 Oct 12.

10.

Antigenically distinct conformations of CXCR4.

Baribaud F, Edwards TG, Sharron M, Brelot A, Heveker N, Price K, Mortari F, Alizon M, Tsang M, Doms RW.

J Virol. 2001 Oct;75(19):8957-67.

11.
12.

Pharmacological properties of peptides derived from stromal cell-derived factor 1: study on human polymorphonuclear cells.

Heveker N, Tissot M, Thuret A, Schneider-Mergener J, Alizon M, Roch M, Marullo S.

Mol Pharmacol. 2001 Jun;59(6):1418-25.

PMID:
11353801
13.

Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.

Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, Alizon M, Scarlatti G, Clavel F, Mammano F.

J Virol. 2001 Jan;75(1):251-9.

14.
16.

Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus.

Richardson J, Pancino G, Merat R, Leste-Lasserre T, Moraillon A, Schneider-Mergener J, Alizon M, Sonigo P, Heveker N.

J Virol. 1999 May;73(5):3661-71.

17.

Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses.

Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, Alizon M.

J Virol. 1999 Apr;73(4):2576-86.

18.

The second extracellular loop of CXCR4 is involved in CD4-independent entry of human immunodeficiency virus type 2.

Reeves JD, Heveker N, Brelot A, Alizon M, Clapham PR, Picard L.

J Gen Virol. 1998 Jul;79 ( Pt 7):1793-9.

PMID:
9680144
19.

The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus.

Willett BJ, Adema K, Heveker N, Brelot A, Picard L, Alizon M, Turner JD, Hoxie JA, Peiper S, Neil JC, Hosie MJ.

J Virol. 1998 Aug;72(8):6475-81. Erratum in: J Virol 1998 Oct;72(10):8460.

20.
21.

Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100.

Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, Alizon M.

J Virol. 1998 Aug;72(8):6381-8.

22.

Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.

Heveker N, Montes M, Germeroth L, Amara A, Trautmann A, Alizon M, Schneider-Mergener J.

Curr Biol. 1998 Mar 26;8(7):369-76.

23.

The rhesus macaque CCR3 chemokine receptor is a cell entry cofactor for HIV-2, but not for HIV-1.

Sol N, Tréboute C, Gomas E, Ferchal F, Shacklett B, Alizon M.

Virology. 1998 Jan 20;240(2):213-20.

24.

Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Sol N, Ferchal F, Braun J, Pleskoff O, Tréboute C, Ansart I, Alizon M.

J Virol. 1997 Nov;71(11):8237-44.

25.

Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Labrosse B, Pleskoff O, Sol N, Jones C, Hénin Y, Alizon M.

J Virol. 1997 Nov;71(11):8230-6.

26.

HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4.

Ugolini S, Moulard M, Mondor I, Barois N, Demandolx D, Hoxie J, Brelot A, Alizon M, Davoust J, Sattentau QJ.

J Immunol. 1997 Sep 15;159(6):3000-8.

PMID:
9300725
27.

Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry.

Pleskoff O, Tréboute C, Brelot A, Heveker N, Seman M, Alizon M.

Science. 1997 Jun 20;276(5320):1874-8.

28.

Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity.

Brelot A, Heveker N, Pleskoff O, Sol N, Alizon M.

J Virol. 1997 Jun;71(6):4744-51.

29.
30.
31.

Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.

Litwin V, Nagashima KA, Ryder AM, Chang CH, Carver JM, Olson WC, Alizon M, Hasel KW, Maddon PJ, Allaway GP.

J Virol. 1996 Sep;70(9):6437-41.

34.

Factors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26.

Lazaro I, Naniche D, Signoret N, Bernard AM, Marguet D, Klatzmann D, Dragic T, Alizon M, Sattentau Q.

J Virol. 1994 Oct;68(10):6535-46.

35.

CD26 antigen and HIV fusion?

Alizon M, Dragic T.

Science. 1994 May 20;264(5162):1161-2; author reply 1162-5. No abstract available.

PMID:
7909962
36.
37.
39.

Can diphtheria toxin be used for gene therapy of human immunodeficiency virus infection?

Caruso M, Tsikas G, Roussel M, Alizon M, Klatzmann D.

AIDS Res Hum Retroviruses. 1992 Dec;8(12):1949-50. No abstract available.

PMID:
1493044
40.
41.
42.

HIV-triggered killing of booby trapped cells prevents viral spread in an HIV-infected cell population.

Caruso M, Tzikas G, Roussel M, Alizon M, Klatzmann D.

Bone Marrow Transplant. 1992;9 Suppl 1:187-8. No abstract available.

PMID:
1354523
43.

Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses.

Chakrabarti L, Guyader M, Alizon M, Daniel MD, Desrosiers RC, Tiollais P, Sonigo P.

Nature. 1987 Aug 6-12;328(6130):543-7.

PMID:
3649576
44.

Genome organization and transactivation of the human immunodeficiency virus type 2.

Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M.

Nature. 1987 Apr 16-22;326(6114):662-9.

PMID:
3031510
45.

Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients.

Brun-Vezinet F, Rey MA, Katlama C, Girard PM, Roulot D, Yeni P, Lenoble L, Clavel F, Alizon M, Gadelle S, et al.

Lancet. 1987 Jan 17;1(8525):128-32.

PMID:
2879971
46.

Genetic variability in human immunodeficiency viruses.

Alizon M, Montagnier L.

Ann N Y Acad Sci. 1987;511:376-84.

PMID:
3439717
47.

Molecular cloning and polymorphism of the human immune deficiency virus type 2.

Clavel F, Guyader M, Guétard D, Sallé M, Montagnier L, Alizon M.

Nature. 1986 Dec 18-31;324(6098):691-5.

PMID:
3025743
48.

Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients.

Alizon M, Wain-Hobson S, Montagnier L, Sonigo P.

Cell. 1986 Jul 4;46(1):63-74.

PMID:
2424612
49.

Lymphadenopathy/AIDS virus: genetic organization and relationship to animal lentiviruses.

Alizon M, Montagnier L.

Anticancer Res. 1986 May-Jun;6(3 Pt B):403-11.

PMID:
3017179
50.

Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus.

Sonigo P, Alizon M, Staskus K, Klatzmann D, Cole S, Danos O, Retzel E, Tiollais P, Haase A, Wain-Hobson S.

Cell. 1985 Aug;42(1):369-82.

PMID:
2410140

Supplemental Content

Loading ...
Support Center